利用生理药代动力学模型优化妊娠期母胎抗体暴露与给药方案
治疗性抗体常超说明书用于妊娠患者,但胎儿暴露程度与发育风险未知。本研究构建包含胎盘新生儿Fc受体(FcRn)表达的PBPK模型,用>2000名非妊娠者、167名孕妇和268名婴儿的数据校准验证,预测英夫利西单抗、阿达木单抗等5种抗体的母胎浓度在2倍范围内,并支持评估兼顾母体疗效与最小胎儿暴露的给药方案。
要点
- PBPK模型可预测多种治疗性抗体在妊娠期的母胎暴露。
- 模型整合胎盘FcRn表达,预测浓度多落在观察值2倍范围内。
- 框架可评估英夫利西单抗和阿达木单抗的妊娠期给药方案。
核心结论
- 包含FcRn个体发育的PBPK框架能预测多种生物制剂的经胎盘转运,并支持妊娠期给药方案优化。
研究设计与样本
- 研究构建了包含胎盘FcRn表达的生理药代动力学(PBPK)模型,用>2000名非妊娠受试者、167名孕妇和268名婴儿的数据进行校准与验证。
主要发现
- 模型预测的母体和胎儿浓度落在观察值2倍范围内的比例:英夫利西单抗54%和50%,阿达木单抗100%和70%,乌司奴单抗38%和41%,维得利珠单抗92%和77%,依那西普75%和33%。
关键数值与推荐
- FcRn介导的经胎盘抗体转运由三个内体区室描述:母体血管内皮细胞、合体滋养层细胞和胎儿血管内皮细胞。
临床怎么用
- 该PBPK框架可用于预测多种生物制剂的经胎盘转运,并评估维持母体治疗水平同时最小化胎儿暴露的给药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic antibodies are often prescribed off-label to pregnant patients to treat inflammatory, autoimmune, or malignant conditions. Despite their broad use, the extent of fetal exposure to such therapeutic antibodies and the risk to fetal development remain largely unknown. Given the ethical challenges to conduct randomized trials in pregnant patients, modeling and simulation approaches offer an opportunity to yield mechanistic insights using data from observational studies. In this study, a physiologically based pharmacokinetic (PBPK) modeling framework was developed to predict maternal and fetal therapeutic antibody exposures throughout pregnancy. The model incorporates expression data on the placental neonatal Fc receptor (FcRn), a receptor critical to transplacental IgG transfer. FcRn-mediated transplacental antibody transfer was described by three endosomal compartments: (1) maternal vascular endothelial cells; (2) syncytiotrophoblast cells; and (3) fetal vascular endothelial cells. The model was calibrated and validated using endogenous IgG concentrations and pharmacokinetic data from > 2,000 non-pregnant subjects, 167 pregnant women, and 268 infants. Overall, the minimal PBPK model adequately captured the observations, with predictions falling within a twofold range of maternal and fetal concentrations as follows: infliximab (54% and 50%), adalimumab (100% and 70%), ustekinumab (38% and 41%), vedolizumab (92% and 77%), and etanercept (75% and 33%). In addition, the PBPK framework supported the evaluation of infliximab and adalimumab dosing regimens that maintain maternal therapeutic levels while minimizing fetal exposure. This study provides a generalizable PBPK framework including FcRn ontogeny, implemented in a user-friendly tool, to predict transplacental transfer of many biologics and to support appropriate dosing regimens throughout pregnancy.
引用
- Kardouh MS, Dunlap TC, Zhong R, et al. Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model. Clin Pharmacol Ther. 2025. PMID: 40181734. doi:10.1002/cpt.3656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。